207 related articles for article (PubMed ID: 29360813)
1. Development and validation of a plasma-based melanoma biomarker suitable for clinical use.
Van Laar R; Lincoln M; Van Laar B
Br J Cancer; 2018 Mar; 118(6):857-866. PubMed ID: 29360813
[TBL] [Abstract][Full Text] [Related]
2. Identification of a Circulating MicroRNA Profile as a Biomarker of Metastatic Cutaneous Melanoma.
Armand-Labit V; Meyer N; Casanova A; Bonnabau H; Platzer V; Tournier E; Sansas B; Verdun S; Thouvenot B; Hilselberger B; Doncescu A; Lamant L; Lacroix-Triki M; Favre G; Pradines A
Acta Derm Venereol; 2016 Jan; 96(1):29-34. PubMed ID: 26039581
[TBL] [Abstract][Full Text] [Related]
3. A plasma microRNA biomarker of melanoma as a personalised assessment of treatment response.
van Laar RK; Lincoln MT; van Laar BJ
Melanoma Res; 2019 Feb; 29(1):19-22. PubMed ID: 30320629
[TBL] [Abstract][Full Text] [Related]
4. Plasma microRNA-21 is associated with tumor burden in cutaneous melanoma.
Saldanha G; Potter L; Shendge P; Osborne J; Nicholson S; Yii N; Varma S; Aslam MI; Elshaw S; Papadogeorgakis E; Pringle JH
J Invest Dermatol; 2013 May; 133(5):1381-4. PubMed ID: 23303460
[No Abstract] [Full Text] [Related]
5. Melanoma with BRAF Mutation in Circulating Cell-free DNA despite no Mutation in the Primary Lesion: A Case Report.
Ashida A; Uhara H; Mikoshiba A; Sakaizawa K; Kumagai N; Koga H; Okuyama R
Acta Derm Venereol; 2016 Jan; 96(1):128-9. PubMed ID: 26123241
[No Abstract] [Full Text] [Related]
6. Sensitive detection of melanoma metastasis using circulating microRNA expression profiles.
Shiiyama R; Fukushima S; Jinnin M; Yamashita J; Miyashita A; Nakahara S; Kogi A; Aoi J; Masuguchi S; Inoue Y; Ihn H
Melanoma Res; 2013 Oct; 23(5):366-72. PubMed ID: 23863473
[TBL] [Abstract][Full Text] [Related]
7. Tumor biomarkers in melanoma.
Ugurel S; Utikal J; Becker JC
Cancer Control; 2009 Jul; 16(3):219-24. PubMed ID: 19556961
[TBL] [Abstract][Full Text] [Related]
8. Serum miR-16: A Potential Biomarker for Predicting Melanoma Prognosis.
Guo S; Guo W; Li S; Dai W; Zhang N; Zhao T; Wang H; Ma J; Yi X; Ge R; Wang G; Gao T; Li C
J Invest Dermatol; 2016 May; 136(5):985-993. PubMed ID: 26829037
[TBL] [Abstract][Full Text] [Related]
9. Circulating Tumour DNA Reflects Tumour Burden Independently of Adverse Events Caused by Systemic Therapies for Melanoma.
Ashida A; Sakaizawa K; Mikoshiba A; Kiniwa Y; Okuyama R
Acta Derm Venereol; 2019 Nov; 99(12):1184-1185. PubMed ID: 31396634
[No Abstract] [Full Text] [Related]
10. Malignant melanoma--markers for progression and prognosis in malignant melanoma.
Geilen CC; Georgieva J; Milling A; Farthmann B
Front Radiat Ther Oncol; 2006; 39():120-126. PubMed ID: 16394675
[No Abstract] [Full Text] [Related]
11. The circulating microRNA-221 level in patients with malignant melanoma as a new tumor marker.
Kanemaru H; Fukushima S; Yamashita J; Honda N; Oyama R; Kakimoto A; Masuguchi S; Ishihara T; Inoue Y; Jinnin M; Ihn H
J Dermatol Sci; 2011 Mar; 61(3):187-93. PubMed ID: 21273047
[TBL] [Abstract][Full Text] [Related]
12. Serum microRNAs as biomarkers for recurrence in melanoma.
Friedman EB; Shang S; de Miera EV; Fog JU; Teilum MW; Ma MW; Berman RS; Shapiro RL; Pavlick AC; Hernando E; Baker A; Shao Y; Osman I
J Transl Med; 2012 Aug; 10():155. PubMed ID: 22857597
[TBL] [Abstract][Full Text] [Related]
13. Identification of plasma microRNAs as new potential biomarkers with high diagnostic power in human cutaneous melanoma.
Fogli S; Polini B; Carpi S; Pardini B; Naccarati A; Dubbini N; Lanza M; Breschi MC; Romanini A; Nieri P
Tumour Biol; 2017 May; 39(5):1010428317701646. PubMed ID: 28466785
[TBL] [Abstract][Full Text] [Related]
14. Decreased serum microRNA-206 level predicts unfavorable prognosis in patients with melanoma.
Tian R; Liu T; Qiao L; Gao M; Li J
Int J Clin Exp Pathol; 2015; 8(3):3097-103. PubMed ID: 26045823
[TBL] [Abstract][Full Text] [Related]
15. Current staging and prognostic factors in melanoma.
Bartlett EK; Karakousis GC
Surg Oncol Clin N Am; 2015 Apr; 24(2):215-27. PubMed ID: 25769707
[TBL] [Abstract][Full Text] [Related]
16. Molecular markers detecting circulating melanoma cells by reverse transcription polymerase chain reaction: methodological pitfalls and clinical relevance.
Nezos A; Lembessis P; Sourla A; Pissimissis N; Gogas H; Koutsilieris M
Clin Chem Lab Med; 2009; 47(1):1-11. PubMed ID: 19055471
[TBL] [Abstract][Full Text] [Related]
17. microRNA-10b is a prognostic biomarker for melanoma.
Saldanha G; Elshaw S; Sachs P; Alharbi H; Shah P; Jothi A; Pringle JH
Mod Pathol; 2016 Feb; 29(2):112-21. PubMed ID: 26743475
[TBL] [Abstract][Full Text] [Related]
18. Circulating biomarkers in malignant melanoma.
Alegre E; Sammamed M; Fernández-Landázuri S; Zubiri L; González Á
Adv Clin Chem; 2015; 69():47-89. PubMed ID: 25934359
[TBL] [Abstract][Full Text] [Related]
19. Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA.
Tan L; Sandhu S; Lee RJ; Li J; Callahan J; Ftouni S; Dhomen N; Middlehurst P; Wallace A; Raleigh J; Hatzimihalis A; Henderson MA; Shackleton M; Haydon A; Mar V; Gyorki DE; Oudit D; Dawson MA; Hicks RJ; Lorigan P; McArthur GA; Marais R; Wong SQ; Dawson SJ
Ann Oncol; 2019 May; 30(5):804-814. PubMed ID: 30838379
[TBL] [Abstract][Full Text] [Related]
20. MCAM/MUC18/CD146 as a Multifaceted Warning Marker of Melanoma Progression in Liquid Biopsy.
Rapanotti MC; Cugini E; Nuccetelli M; Terrinoni A; Di Raimondo C; Lombardo P; Costanza G; Cosio T; Rossi P; Orlandi A; Campione E; Bernardini S; Blot-Chabaud M; Bianchi L
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
